EUVIMEDEUVIMED entdecken
Open Access

Evaluation of Midazolam-Ketamine-Allopregnanolone Combination Therapy against Cholinergic-Induced Status Epilepticus in Rats

Donna A Nguyen, Michael F Stone, Caroline R Schultz iD, Marcio de Araujo Furtado, Jerome Niquet, Claude G Wasterlain, Lucille A Lumley

The Journal of Pharmacology and Experimental Therapeutics · 2024

DOI: 10.1124/jpet.123.001784 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024. Verfasst von Donna A Nguyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Department, US Army Medical Research Institute of Chemical Defense (USAMRICD), Aberdeen Proving Ground, Maryland (D.A.N., M.F.S., C.R.S.…. Hauptthemen laut MEDLINE: Ketamine, Soman, Neurosteroids, Status Epilepticus. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Status epilepticus (SE) is a life-threatening development of self-sustaining seizures that becomes resistant to benzodiazepines when treatment is delayed. Benzodiazepine pharmacoresistance is thought in part to result from internalization of synaptic GABAA receptors, which are the main target of the drug. The naturally occurring neurosteroid allopregnanolone is a therapy of interest against SE for its ability to modulate all isoforms of GABAA receptors. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been partially effective in combination with benzodiazepines in mitigating SE-associated neurotoxicity. In this study, allopregnanolone as an adjunct to midazolam or midazolam-ketamine combination therapy was evaluated for efficacy against cholinergic-induced SE. Adult male rats implanted with electroencephalographic (EEG) telemetry devices were exposed to the organophosphorus chemical (OP) soman (GD) and treated with an admix of atropine sulfate and HI-6 at 1 minute after exposure followed by midazolam, midazolam-allopregnanolone, or midazolam-ketamine-allopregnanolone 40 minutes after seizure onset. Neurodegeneration, neuronal loss, and neuroinflammation were assessed 2 weeks after GD exposure. Seizure activity, EEG power integral, and epileptogenesis were also compared among groups. Overall, midazolam-ketamine-allopregnanolone combination therapy was effective in reducing cholinergic-induced toxic signs and neuropathology, particularly in the thalamus and hippocampus. Higher dosage of allopregnanolone administered in combination with midazolam and ketamine was also effective in reducing EEG power integral and epileptogenesis. The current study reports that there is a promising potential of neurosteroids in combination with benzodiazepine and ketamine treatments in a GD model of SE. SIGNIFICANCE STATEMENT: Allopregnanolone, a naturally occurring neurosteroid, reduced pathologies associated with soman (GD) exposure such as epileptogenesis, neurodegeneration, and neuroinflammation, and suppressed GD-induced toxic signs when used as an adjunct to midazolam and ketamine in a delayed treatment model of soman-induced status epilepticus (SE) in rats. However, protection was incomplete, suggesting that further studies are needed to identify optimal combinations of antiseizure medications and routes of administration for maximal efficacy against cholinergic-induced SE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineSomanNeurosteroidsStatus EpilepticusRatsMaleAnimalsMidazolamPregnanoloneAnticonvulsantsNeuroinflammatory DiseasesSeizuresBenzodiazepinesCholinergic AgentsReceptors, GABA-Agamma-Aminobutyric Acid

Substanzen

MidazolamKetaminePregnanoloneSomanAnticonvulsantsNeurosteroidsBenzodiazepinesCholinergic AgentsReceptors, GABA-Agamma-Aminobutyric Acid

Autor:innen und Institutionen

  • Neuroscience Department, US Army Medical Research Institute of Chemical Defense (USAMRICD), Aberdeen Proving Ground, Maryland (D.A.N., M.F.S., C.R.S., L.A.L.); BioSEaD, LLC, Rockville, Maryland (M.D.A.F.); Department of…

ORCID-Profile: Caroline R Schultz

Förderung

  • NINDS NIH HHS
  • NIH HHS

Zitieren

APA

Nguyen, D. A., Stone, M. F., Schultz, C. R., de Araujo Furtado, M., Niquet, J., Wasterlain, C. G., & Lumley, L. A. (2024). Evaluation of Midazolam-Ketamine-Allopregnanolone Combination Therapy against Cholinergic-Induced Status Epilepticus in Rats. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.001784

Vancouver

Nguyen DA, Stone MF, Schultz CR, de Araujo Furtado M, Niquet J, Wasterlain CG, et al. Evaluation of Midazolam-Ketamine-Allopregnanolone Combination Therapy against Cholinergic-Induced Status Epilepticus in Rats. The Journal of Pharmacology and Experimental Therapeutics. 2024. doi:10.1124/jpet.123.001784

BibTeX
@article{Nguyen2024,
  author = {Nguyen, Donna A and Stone, Michael F and Schultz, Caroline R and de Araujo Furtado, Marcio and Niquet, Jerome and Wasterlain, Claude G and Lumley, Lucille A},
  title = {Evaluation of Midazolam-Ketamine-Allopregnanolone Combination Therapy against Cholinergic-Induced Status Epilepticus in Rats},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  doi = {10.1124/jpet.123.001784}
}
Kostenlos starten →